These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38310990)

  • 1. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
    Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
    J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
    Wang L; Zhou GB; Liu P; Song JH; Liang Y; Yan XJ; Xu F; Wang BS; Mao JH; Shen ZX; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4826-31. PubMed ID: 18344322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
    Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
    J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series.
    Fang YG; Huang SL; Chen NN
    J Integr Med; 2024 Sep; 22(5):614-620. PubMed ID: 39183097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell transcriptomics profiling the compatibility mechanism of As
    Zhang X; Chen H; Huang X; Xu H; Li Y; Yuan H; Yu J; Gao Y
    Biomed Pharmacother; 2022 Jul; 151():113182. PubMed ID: 35643069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
    Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
    Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
    Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
    Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
    Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
    Xie Q; Yu L; Wang X; Wu Z; Zhi D; Yang J; Guo Z; Wu T; Sun Y; Zhao L; Ding X; Khan A; Li H
    Pak J Pharm Sci; 2019 May; 32(3):957-962. PubMed ID: 31278706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.
    Lou Y; Ma Y; Jin J; Zhu H
    Front Oncol; 2020; 10():597601. PubMed ID: 33614484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetra-arsenic tetra-sulfide (As4S 4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
    Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
    Tumour Biol; 2014 Apr; 35(4):3421-30. PubMed ID: 24430359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
    Tian Y; Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
    PLoS One; 2014; 9(1):e83184. PubMed ID: 24454695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
    Huang DP; Yang LC; Chen YQ; Wan WQ; Zhou DH; Mai HR; Li WL; Yang LH; Lan HK; Chen HQ; Guo BY; Zhen ZJ; Liu RY; Chen GH; Feng XQ; Liang C; Wang LN; Li Y; Luo JS; Fan Z; Luo XQ; Li B; Tang YL; Zhang XL; Huang LB
    Blood Cancer J; 2023 Dec; 13(1):178. PubMed ID: 38052803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
    Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
    Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
    Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia.
    Zhang L; Yang XM; Chen J; Hu L; Yang F; Zhou Y; Zhao BB; Zhao W; Zhu XF
    Drug Des Devel Ther; 2021; 15():1633-1640. PubMed ID: 33911851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway.
    Hai Y; Wang X; Song P; Li JY; Zhao LH; Xie F; Tan XM; Xie QJ; Yu L; Li Y; Wu ZR; Li HY
    Arch Pharm Res; 2019 Aug; 42(8):684-694. PubMed ID: 31214877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.
    Huang Q; Wang T; Xiong Y; Qu L; Yin Q; Zou W
    Chin Herb Med; 2022 Jan; 14(1):154-165. PubMed ID: 36120125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.